Related Experiment Video
Updated: Jan 24, 2026

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
Expression of PD-1 and CTLA-4 Are Negative Prognostic Markers in Renal Cell Carcinoma
Andreas Kahlmeyer1, Christine G Stöhr2, Arndt Hartmann3
1Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich Alexander-University Erlangen-Nuernberg, 91054 Erlangen, Germany. andreas.kahlmeyer@uk-erlangen.de.
Abstract:
Immuno-oncological therapy with checkpoint inhibition (CI) has become a new standard treatment in metastatic renal cell carcinoma (RCC), but the prognostic value of the expression of CI therapy target molecules is still controversial. 342 unselected consecutive RCC tumor samples were analyzed regarding their PD-1, PD-L1, and CTLA-4 expression by immunohistochemistry (IHC). The prognostic values for cancer-specific survival (CSS) and overall survival (OS) were analyzed for those not exposed to CI therapy. The expression of PD-1 in tumor-infiltrating mononuclear cells (TIMC) and PD-L1 in tumor cells was detected in 9.4% and 12.3%, respectively (Immune reactive score (IRS) > 0). Furthermore, PD-L1 expression in TIMC (IRS > 0) and CTLA-4 expression in TIMC (>1% positive cells) was detected in 4.8% and 6.3%. PD-1 expression and CTLA-4 expression were significantly associated with a worse OS and CSS in log rank survival analysis and univariate Cox regression analysis. CTLA-4 expression is a prognostic marker that is independently associated with a worse outcome in multivariate Cox regression analysis in the whole cohort (OS: p = 0.013; CSS: p = 0.048) as well as in a non-metastatic subgroup analysis (OS: p = 0.028; CSS: p = 0.022). Patients with combined CTLA-4 expression and PD-1-expression are at highest risk in OS and CSS. In RCC patients, PD-1 expression in TIMC and CTLA-4 expression in TIMC are associated with a worse OS and CSS. The combination of PD-1 expression in TIMC and CTLA-4 expression in TIMC might identify high risk patients. This is, to our knowledge, the first description of CTLA-4 expression to be a prognostic marker in RCC.
Insights
Checkpoint inhibition (CI) therapy is standard for metastatic renal cell carcinoma (RCC). However, PD-1 and CTLA-4 expression in tumor-infiltrating mononuclear cells (TIMC) are linked to worse survival, with CTLA-4 independently predicting poor outcomes.
Area of Science:
- Oncology
- Immunology
- Pathology
Background:
- Immuno-oncological therapy with checkpoint inhibition (CI) is a standard treatment for metastatic renal cell carcinoma (RCC).
- The prognostic significance of CI target molecule expression in RCC remains controversial.
- Understanding these markers can refine patient risk stratification and treatment strategies.
Purpose of the Study:
- To investigate the prognostic value of programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) expression in RCC.
- To determine if these markers predict cancer-specific survival (CSS) and overall survival (OS) in patients not treated with CI therapy.
- To identify potential biomarkers for high-risk RCC patients.
Main Methods:
- Analysis of 342 unselected RCC tumor samples using immunohistochemistry (IHC).
- Quantification of PD-1, PD-L1, and CTLA-4 expression in tumor cells and tumor-infiltrating mononuclear cells (TIMC).
- Survival analysis (log-rank, univariate and multivariate Cox regression) for CSS and OS in patients without prior CI exposure.
Main Results:
- PD-1 expression in TIMC was found in 9.4% and CTLA-4 expression in TIMC in 6.3% of samples.
- Both PD-1 and CTLA-4 expression in TIMC were significantly associated with worse OS and CSS.
- CTLA-4 expression was an independent prognostic marker for worse OS and CSS in multivariate analysis.
- Combined PD-1 and CTLA-4 expression identified patients at the highest risk for poor outcomes.
Conclusions:
- PD-1 and CTLA-4 expression in TIMC are associated with unfavorable survival in RCC patients.
- CTLA-4 expression serves as an independent prognostic marker in RCC.
- The combined assessment of PD-1 and CTLA-4 expression in TIMC may help identify high-risk RCC patients, guiding future therapeutic decisions.
Related Concept Videos
PD Controller: Design
Designing a continuous-data controller requires selecting and linking components like adders and integrators, which are fundamental in Proportional,...
Cell Specific Gene Expression
Negative Regulator Molecules
Time-Domain Interpretation of PD Control
Consider the example of control of motor torque. Initially, a positive...
Positive, Negative, and Zero Work
Chromatin Position Affects Gene Expression
Topologically Associated Domains (TADs)
The 3-dimensional positioning of chromatin in the nucleus influences the...

